Loneliness Is Predictor of Depression, Poor Health Outcomes
By Elana Gotkine HealthDay Reporter
Medically reviewed by Drugs.com
via HealthDayTHURSDAY, July 10, 2025 -- Loneliness is a predictor of depression and poor health outcomes, according to a study published online July 9 in PLOS ONE.
Oluwasegun Akinyemi, M.D., Ph.D., from the Howard University College of Medicine in Washington, D.C., and colleagues examined the association between loneliness and key outcomes, including depression diagnosis, poor mental health days, and poor physical health days, using data from the Behavioral Risk Factor Surveillance System from 2016 to 2023.
The study included 47,318 individuals; more than 80 percent reported some degree of loneliness. The researchers found that individuals who reported being "always" lonely had a significantly higher predicted probability of depression (50.2 versus 9.7 percent), as well as 10.9 more poor mental health days and 5.0 more poor physical health days per month, compared to those who reported "never" being lonely. Across sex, race/ethnicity, and age, disparities were evident. Across most loneliness levels, women consistently reported more poor mental health days than men. Significantly lower probabilities of depression and fewer poor mental health days were seen for Black versus White individuals reporting loneliness. Across all loneliness categories, older adults (older than 64 years) reported more poor physical health days than younger adults.
"Our findings underscore loneliness as a pressing public health issue with wide-reaching effects on mental and physical health," the authors write. "The use of a causal analytic framework and nationally representative data advances the field, making a strong case for upstream interventions."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2025-07-11 12:00
Read more
- FDA Approves Immgolis (golimumab-sldi) and Immgolis Intri (golimumab-sldi) as the First Interchangeable Biosimilars to Simponi and Simponi Aria
- Boehringer Ingelheim’s Novel Glucagon/GLP-1 Dual Agonist Survodutide Achieved Significant Weight Loss and Meaningful Metabolic Improvement in Phase III Trial
- Vitamin D Deficiency Linked to More Pain After Unilateral Breast Cancer Surgery
- Audit Study Reveals Fabricated References Used in Number of Medical Papers
- New Wearable Polygraph Tracks Hidden Stress In Babies, Adults
- Coya Therapeutics Has Been Granted U.S. FDA Fast Track Designation for COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions